NEW YORK, NY / ACCESSWIRE / December 5, 2017 / Both Ionis Pharmaceuticals and GW Pharmaceuticals saw losses on Monday. GW Pharmaceuticals closed down a little over 6% despite announcing fourth quarter results and that it expects a decision from the FDA about its seizure drug Epidiolex by mid next year. Ionis Pharmaceuticals announced recently that it has licensed a second orally delivered Generation 2.5 antisense drug to Janssen Biotech, Inc. which it has a global collaboration agreement with.

RDI Initiates Coverage on:

Ionis Pharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=IONS

GW Pharmaceuticals plc
https://rdinvesting.com/news/?ticker=GWPH

Ionis Pharmaceuticals, Inc. shares closed down 8.20% on nearly 1.3 million shares traded. There was no news yesterday to explain the drop but it was late last month that the company announced that it has licensed a second orally delivered Generation 2.5 antisense drug called IONIS-JBI2-2.5Rx to Janssen Biotech, Inc. The company earned $5 million as a result. Senior vice president of research at Ionis, Frank Bennett, Ph.D. commented, "We are pleased that IONIS-JBI2-2.5Rx is advancing into development because we believe this drug has the potential to treat autoimmune disorders in the GI tract that are underserved with current therapies. Our collaboration with Janssen has been very productive. This is the second drug Janssen has licensed in little over a year, which is the direct result of the speed and efficiency of our antisense technology." Ionis has a global collaboration agreement with Janssen where the company is eligible to receive nearly $800 million in development, regulatory and sales milestone payments and license fees.

Access RDI's Ionis Pharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=IONS

GW Pharmaceuticals plc shares closed down 6.11% on nearly 700,000 shares traded on Monday. The biopharmaceutical company announced its fourth quarter results ended September 30th, 2017. The company reported revenue of £8.2 million and a loss of £131.7 million for the twelve months ended 30 September 2017. This is in comparison to revenue of £10.3 million and a loss of £63.7 million for the twelve months ended 30 September 2016. CEO Justin Gover remarked, "With the Epidiolex NDA for Dravet syndrome and Lennox-Gastaut syndrome submitted, we have entered a very exciting period for GW and look forward to working with the FDA to support its review process. With a decision on the NDA anticipated in mid-2018, we believe we are making excellent progress with preparations to ensure a highly successful US launch if Epidiolex is approved." He also said, "We also expect to submit a European regulatory application for Epidiolex for these indications in late 2017 and are now building a European commercial presence to prepare for a potential future launch." Epidiolex is a CBD-based pharmaceutical drug for the treatment of seizures.

Access RDI's GW Pharmaceuticals plc Research Report at:
https://rdinvesting.com/news/?ticker=GWPH

Our Actionable Research on Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and GW Pharmaceuticals plc (NASDAQ: GWPH) be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com